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of the 61 CIs confirmed that the draft SSA was interpreted as intended by patients, 
and assesses concepts relevant to and experienced by patients across all examined 
cancer types. Minor revisions were made to nine items to improve clarity. One 
additional item was added to ensure comprehensiveness. CONCLUSIONS: The SSA 
demonstrates strong content validity, assessing relevant CaF concepts in a man-
ner patients understand. Planned future development activities include additional 
CIs to confirm content validity of the revised, 14-item SSA in an electronic format, 
followed by an observational study for the development of scoring, item reduction, 
and psychometric validation.
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OBJECTIVES: To assess frequency and type of Patient-Reported Outcomes (PROs) in 
studies of bladder cancer. METHODS: A search of Citeline’s Trialtrove was conducted 
using the search criteria “Bladder Cancer” as the disease, drugs tested was “any”, 
trial phase was II/III, III, and IV, and included planned, ongoing and completed stud-
ies. This resulted in 182 trials. Study design included clinical trials (double-blind, 
open-label) and observational studies. Start dates ranged from 1985-2014. Trials 
were excluded if disease type was other than bladder cancer. The remaining 138 
trials were reviewed to determine prevalence and type of PROs. RESULTS: Only 
27 (7.4%) of the studies included PROs as stated in the endpoints section despite 
bladder cancer being one of the most commonly diagnosed types of cancer in the 
US, especially among men. For these 27 trials, 9 different PROs were identified, 3 of 
which were bladder cancer disease specific. A total of 39 PROs were included with a 
range of 1-2 PROs per study, an average of 1.44 PROs. Thirty-four (87%) of these PROs 
measured Health-Related Quality of Life (HRQL) and 5 (13%) were symptom-based 
measures. Within the HRQL measures, 9 (26.5%) were cancer general, 9 (26.5%) were 
specific to Bladder Cancer, 1 (3%) was generic (e.g., SF-36), and the remaining 15 
(44%) were not specified. Among the symptom measures, 3 (60%) were specific to 
bladder cancer and 2 (40%) were generic. CONCLUSIONS: Results indicate that the 
prevalence of PROs in bladder cancer trials is low compared to other cancers (e.g., 
ovarian cancer) and other diseases despite their importance in evaluating impact 
of disease and treatment benefit. The type of PRO most commonly indicated was a 
bladder cancer disease-specific measure of HRQL. Findings show the need to high-
light the value and relevance of patient-reported data to increase incorporation of 
PROs in bladder cancer trials.
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OBJECTIVES: To assess use of Patient-Reported Outcomes (PROs) in studies of 
Ovarian Cancer. METHODS: A search of Citeline’s Trialtrove was conducted using 
the search criteria of “Ovarian Cancer” as the disease, drugs tested was “any,” and 
trial phase was II/III, III, and IV. This resulted in 252 trials. Studies were excluded 
if the disease type was other than ovarian cancer. Study designs were clinical trial 
and observational studies, and both double-blind and open-label studies were 
included. Target accrual for all studies was ≥ 53. Start dates ranged from 1990 
to 2014. The remaining 189 trials were then assessed for prevalence and type of 
PROs. RESULTS: Of the 189 studies reviewed, 102 (54%) included PROs. For these 
102 trials, a total of 148 PROs were included, and an average of 1.5 PROs were 
used per study with a range of 1 to 4. A total of 15 different PROs were identified. 
One hundred twenty-six (85%) of these PROs measured Health-Related Quality of 
Life (HRQL), 10 (7%) measured QoL/Utilities, 9 (6%) measured Symptoms, 2 (1%) 
measured Activities of Daily Living and 1 (1%) was categorized as other. Within 
the HRQL measures, 35 (28%) were ovarian cancer specific measures, 27 (21%) 
were cancer general measures, 6 (5%) were cancer treatment specific, 2 (2%) were 
generic measures and 1 (1%) was chemotherapy treatment specific. The remaining 
55 (43%) HRQL endpoints were unspecified. CONCLUSIONS: PROs are included in 
ovarian cancer clinical studies approximately half the time, which is low compared 
to other disease areas. The majority of measures assess HRQL and are specific to 
ovarian cancer. Including HRQL in ovarian cancer studies can support the value of 
progression free survival to patients. PROs can be used to show the value of new 
ovarian cancer drug therapies.
PCN123
does the geNeRiC CaNCeR outCome measuRe eoRtC qlq-C30 woRk iN 
myelofiBRosis?
Mukuria CW, Brazier J, Rafia R
University of Sheffield, Sheffield, UK
OBJECTIVES: The EORTC QLQ-C30 is a validated patient reported outcome measure 
for cancer patients but there is limited evidence on its validity in Myelofibrosis 
(MF), a rare but serious bone-marrow cancer. This study aimed to provide evi-
dence of its validity in MF. METHODS: QLQ-C30 was compared to MF specific 
measures (MF-SAF 2.0 and FACT-Lym) using trial data of MF patients (COMFORT I 
(n= 309) and COMFORT II (n= 219)). Convergent validity based on correlation analy-
sis, known group analysis based on MF specific measures using Cohen’s d effect 
size (ES) and responsiveness based on standardised response mean (SRM) were 
undertaken. RESULTS: QLQ-C30 dimensions (physical, role, emotional and social 
functioning, pain and fatigue) were strongly correlated (ρ > 0.5) with equivalent 
items/dimensions in the MF-SAF and FACT-Lym but all QLQ_C30 dimensions were 
weakly correlated (ρ < 0.3) to MF symptoms such as weight loss, itching and night 
sweats. Most QLQ-C30 dimensions were able to discriminate between MF-SAF 
(scores 0-10; 11-20; 21-30; 31-60) with better discrimination for the mild severity 
low score groups (0.2< ES< 0.7) compared to high score groups (ES< 0.2) who had 
higher severity and the FACT-Lym (scores 0-30; 31-40; 41-50; 51-60) groups. SRMs 
were < 0.2 for most QLQ-C30 dimensions including pain but > 0.2 for MF-SAF and 
PCN118
taste dysfuNCtioN afteR head aNd NeCk CaNCeR tReatmeNt: a  
meta-aNalysis
McLaughlin L.A.
Saint Louis University, St. Louis, MO, USA
OBJECTIVES: Taste dysfunction is a common, debilitating problem for head and 
neck cancer treatment survivors (HNCTS). When taste is impaired eating is not as 
enjoyable, appetite is diminished and overall health related quality of life (HRQoL) 
is diminished. However, the extent to which taste impairment in HNCTS remains 
altered over time is not well understood. METHODS: The Ovid MEDLINE®, SCOPUS, 
and CINAHL data bases were searched for reports of HNCTS in which taste function 
was measured. Eligible studies compared taste scores baseline to up to five years 
post treatment. 3872 reports were identified in the literature search and 20 studies 
were suitable for inclusion in the final analysis. Estimates of effect size of head 
and neck cancer therapy on taste dysfunction were extracted from each study. 
A descriptive meta-analysis was conducted using Comprehensive Meta-analysis 
software (Version 2, Biostat, Englewood, NJ). RESULTS: The meta-analysis included 
data on 1526 subjects. The sample was predominantly young in age (mean age is 
59.11 years) and 66.8% male. Head and neck cancer treatment survivors reported 
statistically significantly worse taste scores 6 months or longer after completing all 
cancer treatment. The summary effect for the standard measure difference between 
pretreatment and post-treatment taste scores was 0.331 (p= < 0.001). The sample 
was highly heterogeneous in terms of country, tumor site, and therapy, so a random 
effects model was chosen for data analysis. Heterogeneity testing supported this 
decision (Q= 82.08, df 18, p < 0.001). CONCLUSIONS: Assessment of HRQoL in HNCTS 
should include questions on taste function. With the global increase in HPV related 
head and neck cancers, the pool of treatment survivors is expected to increase over 
the next decade. The Taste dysfunction is a long-term complication for HNCTS and 
clinicians should screen survivors for this sensory dysfunction.
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OBJECTIVES: The US Food and Drug Administration (FDA) did not approve any 
PRO label claims for cancer treatments between 2006 and 2010. In December 2009, 
the agency published guidance on the use of PROs to support label claims, and 
in 2012 the Center for Medical Technology Policy (CMTP) called for all prospec-
tive comparative studies of oncology drugs in adults to include PRO measures. 
The current study sought to identify how many PRO claims have been approved 
since the publication of these documents, to consider the challenges for sponsors 
seeking such claims, and offer solutions to these challenges. METHODS: The FDA 
website was searched for approvals of hematology and oncology drugs 2010–2014. 
The most recently approved labels of eligible products and drug approval packages 
were reviewed for comments on PRO data. RESULTS: Of 64 drug labels suitable 
for review, two had PRO efficacy claims: ruxolitinib (myelofibrosis) was claimed to 
improve symptoms, as measured by the Myelofibrosis Symptom Assessment Form; 
abiraterone acetate (prostate cancer) was claimed to improve pain, as measured 
by the Brief Pain Inventory (BPI-SF). For crizotinib (NSCLC), PROs were used to sup-
port adverse event reporting (vision disorders). The label for brentuximab stated 
that no improvement in patient-reported symptoms for either indication (Hodgkin 
lymphoma and anaplastic large cell lymphoma) had been established. A further 
12 labels stated that there were no data to demonstrate improvement in disease-
related symptoms. CONCLUSIONS: This review demonstrates the emergence of 
PRO label claims for oncology products, despite the recent FDA and CMTP guidance 
PRO data are infrequently documented in FDA-approved oncology labels. Labels 
increasingly specify when there is an absence of symptom data e.g. brentuximab, 
carfilzomib, marking a shift in FDAs expectations. Sponsors face challenges such as 
a lack of validated tumor-specific instruments. A strategic four-step PRO endpoint 
development process provides a way forward.
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OBJECTIVES: Cancer-related fatigue (CaF) is a common symptom of cancer and one 
that can be burdensome to patients. It is possibly under-reported due to its complex 
origins, inconsistent definitions and assessment methods. In recent years, no exist-
ing measures have been accepted by the US Food and Drug Administration (FDA) to 
support labeling claims in CaF. The Patient-Reported Outcomes of Fatigue in Cancer 
(PROOF-C) Consortium have developed the Symptom Severity Assessment (SSA), a 
patient-reported outcome (PRO) measure of CaF to be aligned with FDA expectations 
as part of the FDA’s Drug Development Tool (DDT) Qualification Program. METHODS: 
In total 91 open-ended concept elicitation (CE) interviews were conducted among 
eight cancer types to spontaneously elicit the patient experience of CaF. Items 
were generated based on qualitative, thematic analysis of verbatim transcripts and 
with input from a clinical expert. Subsequently, 61 cognitive interviews (CIs) were 
conducted with patients in six cancer types, wherein a “think-aloud” process and 
targeted debriefing questions were used to assess concept relevance and patients’ 
understanding of the instructions, items, and response options. RESULTS: CE data 
supported the development of a draft, 13-item SSA, measuring eight symptoms of 
CaF, with a 24-hour recall period and an 11-point numeric rating scale. The results 
